Phase 3 N=829 Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis
Ulcerative Colitis
Primary: Endoscopic Remission of Ulcerative Colitis (UC) at 6 Months — 83.7; 81.5 percent of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis
Ulcerative Colitis
Primary: Percentage of Participants Achieving Endoscopic Improvement — 16.7 percentage of participants
Phase 2 N=105 A Trial of Rosiglitazone for Ulcerative Colitis
Ulcerative Colitis · Inflammatory Bowel Disease
Primary: Number of Participants With Improvement of Signs and Symptoms of UC at 12 Weeks — 23; 12 participants — p=.005
N/A N=19 The Impact of Circadian Misalignment on Colonic Barrier Homeostasis in Ulcerative Colitis
Ulcerative Colitis
Primary: Change in Dim Light Melatonin Onset (DLMO) From Baseline (Aligned) to Circadian Misalignment Misalignment — 20.72; 20.45; 23.05; 22.65 hours
N/A N=326 A Study of Moderate to Severe Inflammatory Bowel Disease, Including Ulcerative Colitis (UC) and Crohn's Disease (CD)
Inflammatory Bowel Diseases · Colitis, Ulcerative · Crohn Disease
Primary: Percentage of Participants With Active CD at Day 1 — 45.3 percentage of participants
Phase 2 N=211 The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis
Ulcerative Colitis
Primary: Clinical Remission — 5; 2; 9; 4 Participants — p=0.1806
Phase 2 N=50 Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis.
Colitis, Ulcerative
Primary: Number of Participants With Treatment-Emergent Adverse Events, Serious Adverse Events, and Who Withdrew Due to Adverse Events — 33; 3; 8; 1 Participants
Phase 3 N=1,012 Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis
Ulcerative Colitis
Primary: Percentage of Participants in Clinical Remission at 10 Weeks — 18.4; 6.0; 21.0 Percentage — p=0.0001
N/A N=15 Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity
Ulcerative Colitis
Primary: Number of Relapses by Group — 0; 3 relapses — p=0.046
Phase 2 N=249 A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis
Ulcerative Colitis
Primary: Induction Period: Percentage of Participants With Clinical Remission at Week 12 — 4.8; 15.9; 22.6; 11.5 percentage of participants
Phase 2 N=22 Efficacy, Pharmacodynamics, Safety and Tolerability of Oral BL-7040 in Patients With Moderately Active Ulcerative Colitis
Ulcerative Colitis
Primary: Proportion of Patients Who After Study Completion Achieve Clinical Response Defined by at Least a 3point Decrease & 30% Reduction From Baseline in Mayo Score Plus ≥ 1…
Phase 2 N=124 An Exploratory Study of Rebamipide in Patients With Active Ulcerative Colitis
Colitis, Ulcerative
Primary: Clinical Improvement Rate (Number of Subjects Showing Clinical Improvement/Number of Subjects Evaluated x 100) — 31.4; 24.1; 44.4; 30.0 percentage of participants
Phase 2 N=170 Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
Ulcerative Colitis
Primary: Percentage of Participants Who Achieved a Clinical Remission by Total Mayo Score (TMS) at Week 12 — 12.1; 31.6; 21.8 Percentage of Participants — p=0.0142
Phase 1 N=18 Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission
Ulcerative Colitis
Primary: Number of Participants With Clinical Toxicity Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version (v.) 4.0 — 2; 0…
Phase 2 N=78 Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis
Colitis, Ulcerative
Primary: Number of Participants With Any Adverse Events (AE) or Serious Adverse Events (SAE) — 10; 7; 9; 6 Participants
Phase 2 N=144 A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)
Moderate to Severe Ulcerative Colitis
Primary: Change From Baseline for Adapted Mayo Score: 0.2 mg Versus Placebo — -2.60; -1.95 score on a scale
Phase 2 N=124 An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis
Colitis, Ulcerative
Primary: Number of Subjects Who Achieve Clinical Remission at Week 8 Using Modified Mayo Score. — 7; 12 Participants — p=0.106
Phase 2 N=357 A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis
Ulcerative Colitis
Primary: Percentage of Participants in Clinical Remission at Week 12 — 2.7; 11.3; 16.7; 15.5 percentage of participants — p=0.0213
Phase 2 N=66 Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
Ulcerative Colitis · Digestive System Diseases · Colitis, Ulcerative
Primary: Number of Subjects With Treatment-related Adverse Events — 5; 7; 7; 14 Participants
Phase 2 N=6 Oral OKT3 for the Treatment of Active Ulcerative Colitis
Ulcerative Colitis
Primary: Number of Participants With Adverse Events — 3 Participants
N/A N=4 Mucosal Immunity of Ulcerative Colitis Patients Undergoing Therapy With Trichuris Suis Ova
Ulcerative Colitis
Primary: Change From Baseline of Mucus Production at 12 Weeks and 24 Weeks as Assessed by Histopathology
Phase 2 N=59 A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis
Ulcerative Colitis
Primary: Number of Participants Experiencing a Treatment Emergent Adverse Event — 3; 9; 10 participants
Phase 2 N=224 Phase II Study of HMPL-004 in Patients With Ulcerative Colitis
Ulcerative Colitis
Primary: Number of Participants With a Clinical Response at Week 8 — 33; 45; 30 Participants
Phase 3 N=591 A Study of Abatacept in Patients With Active Ulcerative Colitis
Ulcerative Colitis
Primary: Induction Period (IP); Number of Participants With Clinical Response (Per Mayo Score) at Week 12: IP Cohort 1 (IP1C) — 30; 26; 14; 41 participants — p=0.124
Phase 1 N=26 Low Dose IL-2 for Ulcerative Colitis
Ulcerative Colitis
Primary: Number of Subjects With Serious and Non-serious Adverse Events. — 0; 0; 0 Participants
Phase 2 N=105 A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis
Colitis, Ulcerative
Primary: Change From Baseline in Endoscopic Score (as Measured by Modified Baron Score) at Week 8 — 3.13; 3.10; 0.10; -0.30 scores on a scale — p=0.96
Phase 3 N=1,447 An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Ulcerative Colitis
Primary: Percentage of Participants With Clinical Remission at Week 12 — 13.3; 24.2 percentage of participants — p=0.00006
Phase 2 N=27 Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Dietary Fiber in Patients With Ulcerative Colitis
Ulcerative Colitis · Inflammatory Bowel Diseases
Primary: Clinical Response — 5; 2; 1 Participants
Phase 3 N=121 A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)
Colitis, Ulcerative
Primary: Percentage of Participants With Clinical Remission at Week 54 Based on Modified Mayo Score — 51.1; 43.5 percentage of participants
Phase 2 N=32 ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
Ulcerative Colitis
Primary: Number of Subjects With Treatment-emergent Adverse Events — 18; 5 Participants — p=0.2096